Athersys, Inc. (NASDAQ:ATHX) – William Blair dropped their Q1 2018 EPS estimates for shares of Athersys in a report released on Wednesday, March 14th, according to Zacks Investment Research. William Blair analyst Y. Xu now forecasts that the biopharmaceutical company will post earnings per share of ($0.10) for the quarter, down from their previous forecast of ($0.09). William Blair also issued estimates for Athersys’ Q2 2018 earnings at ($0.02) EPS, Q3 2018 earnings at ($0.10) EPS, Q4 2018 earnings at ($0.11) EPS, FY2018 earnings at ($0.34) EPS and FY2019 earnings at ($0.51) EPS.
Athersys (NASDAQ:ATHX) last issued its earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.04). Athersys had a negative net margin of 869.50% and a negative return on equity of 123.22%. The business had revenue of $1.17 million for the quarter, compared to analysts’ expectations of $0.42 million. During the same quarter in the prior year, the business posted ($0.10) earnings per share. The business’s revenue for the quarter was up 19.0% on a year-over-year basis.
Several other analysts also recently commented on the company. ValuEngine upgraded Athersys from a “sell” rating to a “hold” rating in a research note on Thursday, March 22nd. Maxim Group restated a “buy” rating and issued a $6.00 price target on shares of Athersys in a research note on Tuesday, March 13th.
ATHX traded down $0.11 during trading on Friday, hitting $1.81. 458,135 shares of the company’s stock traded hands, compared to its average volume of 646,918. Athersys has a 12-month low of $1.29 and a 12-month high of $2.63. The company has a market cap of $241.59, a price-to-earnings ratio of -6.24 and a beta of -0.85.
In related news, EVP John J. Harrington sold 15,000 shares of the firm’s stock in a transaction on Friday, March 16th. The stock was sold at an average price of $1.84, for a total value of $27,600.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider William Lehmann, Jr. sold 14,000 shares of the firm’s stock in a transaction on Tuesday, March 20th. The stock was sold at an average price of $1.89, for a total value of $26,460.00. Following the completion of the transaction, the insider now directly owns 481,973 shares in the company, valued at $910,928.97. The disclosure for this sale can be found here. Company insiders own 9.40% of the company’s stock.
A number of institutional investors have recently made changes to their positions in ATHX. Wells Fargo & Company MN raised its holdings in Athersys by 102.0% in the 2nd quarter. Wells Fargo & Company MN now owns 123,576 shares of the biopharmaceutical company’s stock worth $187,000 after purchasing an additional 62,400 shares during the period. Northern Trust Corp raised its holdings in Athersys by 30.8% in the 2nd quarter. Northern Trust Corp now owns 1,123,870 shares of the biopharmaceutical company’s stock worth $1,697,000 after purchasing an additional 264,549 shares during the period. Vanguard Group Inc. raised its holdings in Athersys by 9.4% in the 2nd quarter. Vanguard Group Inc. now owns 4,265,772 shares of the biopharmaceutical company’s stock worth $6,441,000 after purchasing an additional 366,572 shares during the period. State Street Corp raised its holdings in Athersys by 27.2% in the 2nd quarter. State Street Corp now owns 1,432,695 shares of the biopharmaceutical company’s stock worth $2,161,000 after purchasing an additional 305,944 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in Athersys by 345.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 88,561 shares of the biopharmaceutical company’s stock worth $134,000 after purchasing an additional 68,680 shares during the period. 19.29% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This piece was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/brokers-issue-forecasts-for-athersys-inc-s-q1-2018-earnings-athx.html.
Athersys Company Profile
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Get a free copy of the Zacks research report on Athersys (ATHX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.